BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
BioAge Labs, Inc.NASDAQ: BIOA
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $52.89M, compared with -$96.86M a year earlier. Trailing-twelve-month net change in cash was -$15.71M. Over 3 fiscal years it compounded at +70.2% a year.
Context
- Net change in cash amounted to 1839.5% of revenue in FY2025.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near $52.89M or moves back toward the trailing-twelve-month quarterly average of -$3.93M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (165.46M) USD
- Year-over-year change
- -150.2%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (165.46M) | -150.2% |
| FY2024 | 2024-12-31 | 329.39M | +12358.7% |
| FY2023 | 2023-12-31 | (2.69M) | +92.0% |
| FY2022 | 2022-12-31 | (33.54M) | — |
Net Change in Cash vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -119.6% is the 7th highest of 9, against a peer median of +19.0%.
- Net change in cash amounts to 152.3% of revenue for BIOA, versus a peer median of 32.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$278.14M CAD | +592.4% | — | 89.0% | |
| LTM Mar 2026 | CA$72.73M CAD | -396.2% | -21.9% | 23.4% | |
| LTM Mar 2026 | $64.45M USD | +2324.8% | -13.1% | 3197.0% | |
| LTM Mar 2026 | $40.08M USD | -3.5% | — | — | |
| LTM Mar 2026 | $16.25M USD | -123.4% | — | 42.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $15.71M USD | -119.6% | +70.2% | 152.3% |
| LTM Mar 2026 | $15.2M USD | -65.0% | +25.9% | — | |
| LTM Mar 2026 | $12.15M USD | +41.5% | -40.4% | — | |
| LTM Mar 2026 | $3.42M USD | — | — | 2.5% | |
| LTM Mar 2026 | $929K USD | +105.1% | — | 2.2% | |
| Peer median (excluding BIOA) | — | +19.0% | -17.5% | 32.7% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.